Tumor markers: myths and facts unfolded

被引：42
作者：
Faria, S. C. [1 ,3 ]
Sagebiel, T. [1 ]
Patnana, M. [1 ]
Cox, V. [1 ]
Viswanathan, C. [1 ]
Lall, C. [2 ]
Qayyum, A. [1 ]
Bhosale, P. R. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA
[2] Univ Florida, Jacksonville, FL USA
[3] 1400 Pressler St Unit 1473, Houston, TX 77030 USA
来源：
ABDOMINAL RADIOLOGY | 2019年 / 44卷 / 04期
关键词：
Tumor markers; Carcinoembryonic antigen; Prostate-specific antigen; Alpha-fetoprotein; Carbohydrate antigen 19-9; Carbohydrate antigen 125; Beta subunit of human chorionic gonadotropin; Lactate dehydrogenase; Chromogranin A; PROSTATE-SPECIFIC ANTIGEN; SERUM CARCINOEMBRYONIC ANTIGEN; COLORECTAL LIVER METASTASES; GERM-CELL TUMORS; HEPATOCELLULAR-CARCINOMA; OVARIAN-CANCER; ALPHA-FETOPROTEIN; CLINICAL UTILITY; EUROPEAN-GROUP; DOUBLING TIME;
D O I：
10.1007/s00261-018-1845-0
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
ObjectiveThe purpose of this article is to review the most commonly used tumor markers in abdominal and pelvic tumors, describe their limitations and explain how to use them in the context of known cancer in order to optimize multidisciplinary care of oncologic patients.ConclusionTumor markers are important for the diagnosis, staging, monitoring of treatment and detection of recurrence in many cancers. This knowledge is crucial in the daily interpretation of images of oncologic and non-oncologic patients. However, radiologists should also be aware of the limitations of the most commonly used tumor markers and they should not be used solely, but interpreted in conjunction with diagnostic imaging, clinical history and physical examination that will help optimize the multidisciplinary care and management of oncologic patients.
引用
收藏
页码：1575 / 1600
页数：26
相关论文
共 111 条
[1]   A Review on the Clinical Utility of PSA in Cancer Prostate [J].
Mohan Adhyam ;
Anish Kumar Gupta .
Indian Journal of Surgical Oncology, 2012, 3 (2) :120-129
[2]   Serum tumour markers in gynaecological cancers [J].
Aggarwal, Pakhee ;
Kehoe, Sean .
MATURITAS, 2010, 67 (01) :46-53
[3]   Detection of locally radio-recurrent prostate cancer at multiparametric MRI: Can dynamic contrast-enhanced imaging be omitted? [J].
Alonzo, F. ;
Melodelima, C. ;
Bratan, F. ;
Vitry, T. ;
Crouzet, S. ;
Gelet, A. ;
Rouviere, O. .
DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2016, 97 (04) :433-441
[4]   HE4: a new potential early biomarker for the recurrence of ovarian cancer [J].
Anastasi, Emanuela ;
Marchei, Giulia Giovanna ;
Viggiani, Valentina ;
Gennarini, Giuseppina ;
Frati, Luigi ;
Reale, Maria Gabriella .
TUMOR BIOLOGY, 2010, 31 (02) :113-119
[5]   Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers [J].
Aslam, Muhammad Imran ;
Kelkar, Ashish ;
Sharpe, David ;
Jameson, John Stuart .
INTERNATIONAL JOURNAL OF SURGERY, 2010, 8 (04) :305-313
[6]   Prostate cancer [J].
Attard, Gerhardt ;
Parker, Chris ;
Eeles, Ros A. ;
Schroder, Fritz ;
Tomlins, Scott A. ;
Tannock, Ian ;
Drake, Charles G. ;
de Bono, Johann S. .
LANCET, 2016, 387 (10013) :70-82
[7]  
Bajetta E, 1999, CANCER, V86, P858, DOI 10.1002/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO
[8]  
2-8
[9]  
BALESTRERI L, RADIOL MED, V104, P426
[10]   Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review [J].
Ballehaninna U.K. ;
Chamberlain R.S. .
Indian Journal of Surgical Oncology, 2011, 2 (2) :88-100
12345678910